Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 5/20 | 0.69 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.58 |
| ▸ | IGF1R | P08069 | 4/20 | 0.57 |
| ▸ | SGK1 | O00141 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 3/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171110 | 0.90 | CAMKK2 (0.73) | CAMKK2RIPK1IGF1RSGK1KIT | |
| SCHEMBL12274266 | 0.89 | CAMKK2 (0.66) | CAMKK2RIPK1IGF1RSGK1KIT | |
| SCHEMBL3761720 | 0.89 | CAMKK2 (0.66) | CAMKK2RIPK1IGF1RSGK1KIT | |
| SCHEMBL3692347 | 0.86 | CAMKK2 (0.69) | CAMKK2RIPK1IGF1RSGK1KIT | |
| SCHEMBL3767383 | 0.83 | CAMKK2 (1.00) | CAMKK2RIPK1IGF1RSGK1KIT | |
| SCHEMBL3770773 | 0.82 | CAMKK2 (0.85) | CAMKK2SGK1KITAXLNTRK1 | |
| SCHEMBL3692345 | 0.81 | CAMKK2 (0.67) | CAMKK2RIPK1IGF1RSGK1KIT | |
| SCHEMBL3768000 | 0.81 | CAMKK2 (0.79) | CAMKK2RIPK1SGK1AXLPIK3CG | |
| SCHEMBL3759378 | 0.80 | CAMKK2 (0.77) | CAMKK2RIPK1SGK1KITAXL | |
| SCHEMBL3757388 | 0.79 | CAMKK2 (0.76) | CAMKK2SGK1KITAXLNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | claimed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | claimed |
| WO-2021006707-A1 | USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES | 한양대학교 산학협력단 | 2021-01-14 | — | — | WO | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | CAMKK2 157/4885RIPK1 143/4885IGF1R 1254/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | CAMKK2 125/4885RIPK1 161/4885IGF1R 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.